MCF-7-luc Orthotopic Mouse Model Service for Breast Cancer

The MCF-7-luc orthotopic model pairs the well-established estrogen receptor–positive luminal A biology of MCF-7 with a stably integrated firefly luciferase reporter, enabling non-invasive, quantitative visualization of tumor engraftment dynamics and treatment-induced volumetric changes in living animals. Alfa Cytology builds and validates this BLI-enabled platform under synchronized estrogen supplementation protocols, delivering longitudinal photon-flux datasets alongside conventional caliper measurements to give your endocrine therapy or CDK4/6 inhibitor program a dual-readout preclinical foundation with exceptional temporal resolution.

Overview of MCF-7-luc Orthotopic Mouse Model for Breast Cancer

MCF-7-luc is a genetically engineered derivative of the parental MCF-7 human breast adenocarcinoma cell line, in which the firefly luciferase 2 (Luc2) gene has been stably integrated under the control of the human EF1α promoter via lentiviral transduction. This reporter cassette permits quantitative, ATP-dependent bioluminescence output that directly correlates with viable cell mass, making it possible to track tumor establishment, exponential growth, and therapeutic regression longitudinally without interim euthanasia. The parental MCF-7 line—established in 1973 from a pleural effusion of a 69-year-old woman—retains its canonical luminal A phenotype in the luciferase-engineered derivative: estrogen receptor α (ERα) positive, progesterone receptor (PR) positive, HER2 negative, and wild-type TP53. Like the parental line, MCF-7-luc requires exogenous estrogen support for robust in vivo proliferation in immunodeficient hosts, because athymic nude and NSG mice lack ovarian steroid production at levels sufficient to sustain ER-driven tumor growth. When implanted orthotopically into the mammary fat pad of estrogen-primed mice, MCF-7-luc cells engraft with high fidelity and generate a bioluminescent signal that rises proportionally with tumor volume, providing a real-time, orthogonal readout of disease burden that complements traditional caliper-based metrics.

Fig 1. (A) MCF-7 orthotopic breast tumor model in nude mice; (B) H&E staining of tumor tissue; (C) VEGFR2 immunofluorescence; (D) p53 IHC staining. (Xu, Li, et al., 2018)

The incorporation of luciferase into the MCF-7 system transforms what is already the most cited breast cancer cell line in the literature into a dynamic, image-guided preclinical instrument. Because the bioluminescent reaction depends on intracellular ATP, signal intensity reflects not merely tumor size but the metabolic viability of the tumor cell population—offering a sensitive early indicator of drug-induced cytotoxicity or cytostasis that may precede measurable changes in physical dimensions. This property is particularly valuable for evaluating endocrine therapies, where cytostatic rather than cytotoxic mechanisms dominate, and for CDK4/6 inhibitors such as palbociclib, which arrest cells in G1 without immediate volumetric shrinkage. The model has been successfully deployed with IVIS® and comparable in vivo imaging systems to monitor tumor kinetics at 1, 3, and 5 weeks post-implantation, and can be extended to detect occult micrometastatic deposits or residual disease foci below the palpation threshold. For preclinical teams seeking to bridge static endpoint analysis with temporal pharmacodynamics, the MCF-7-luc orthotopic xenograft offers an unparalleled combination of biological authenticity, technical accessibility, and quantitative precision.

Cell Line Information: MCF-7-luc

MCF-7-luc is a reporter-engineered derivative of the Michigan Cancer Foundation-7 breast adenocarcinoma line, stably transduced with a codon-optimized firefly luciferase 2 (Luc2) cassette under constitutive EF1α promoter control. The luciferase insertion does not alter the fundamental ER-positive, luminal A biology of the parental line, and the derivative has been validated for comparable in vitro growth kinetics and in vivo tumorigenicity. The table below summarizes the essential characteristics of MCF-7-luc as applied in orthotopic xenograft preclinical research.

Our Services

Alfa Cytology maintains MCF-7-luc under dual-selection culture conditions to preserve luciferase expression fidelity, with each batch authenticated by STR profiling against the ATCC HTB-22-LUC2 reference, routine mycoplasma screening, and pre-implantation BLI signal validation. Our integrated imaging and surgical teams synchronize estrogen pellet priming with orthotopic cell delivery, ensuring that bioluminescence baseline is established within the first week and that longitudinal photon-flux trajectories remain reproducible across cohorts—providing your program with a temporally resolved, quantifiable preclinical dataset.

Workflow of MCF-7-luc Orthotopic Mouse Model Construction

Deploying the MCF-7-luc orthotopic model demands coordinated execution across estrogen priming, luciferase-expression cell banking, matrix-assisted surgical implantation, and longitudinal bioluminescence surveillance. The luciferase reporter adds a critical quality-control layer: signal intensity must be verified in vitro before inoculation to ensure that downstream BLI readouts are interpretable and quantitative. The workflow below integrates these elements into a streamlined protocol optimized for image-guided endocrine therapy and cell-cycle inhibitor studies.

1. Estrogen Priming & Pellet Implantation: Female athymic nude or NSG mice aged 4–6 weeks are acclimatized for 5–7 days. One to three days prior to tumor cell inoculation, each mouse receives a subcutaneous 17β-estradiol slow-release pellet (0.72 mg, 60-day formulation) implanted between the scapulae via a trocar under brief isoflurane anesthesia. Alternatively, estradiol benzoate (50 µg in sesame oil) is administered subcutaneously twice weekly beginning 3 days pre-inoculation. Pellet release kinetics are verified by vendor certificate of analysis.
2. Cell Authentication & Luciferase Validation: MCF-7-luc cells are thawed from a master cell bank verified by STR profiling against the ATCC HTB-22-LUC2 reference standard and confirmed negative for mycoplasma by PCR. Cells are expanded in complete growth medium under antibiotic selection (puromycin or G418, depending on construct) to maintain reporter expression. Prior to in vivo use, luciferase activity is validated by D-luciferin substrate assay on a luminometer; only batches with signal intensity correlating linearly with cell number (r² > 0.98) are approved for implantation.
3. Cell Harvest & Matrix Preparation: On the day of surgery, subconfluent MCF-7-luc cells are detached with trypsin-EDTA, washed twice in sterile PBS, and counted via hemocytometer with trypan blue viability assessment. The final suspension is prepared at 2 × 10⁷ cells/ml in ice-cold PBS and mixed 1:1 (v/v) with chilled, phenol red–free basement membrane matrix to achieve a final concentration of 1 × 10⁶ cells per 100 µl. The mixture is kept on ice until injection to prevent premature gelation.
4. Animal Preparation & Anesthesia: Estrogen-primed mice are anesthetized with isoflurane (2–3% in medical oxygen) via precision vaporizer and nose cone. The lower abdominal surgical field—centered on the 4th inguinal mammary gland—is shaved, depilated if necessary, and sterilized sequentially with povidone-iodine and 70% ethanol. Body temperature is maintained on a heated surgical pad throughout the procedure.
5. Orthotopic Mammary Fat Pad Implantation: A 100 µl suspension containing 1 × 10⁶ MCF-7-luc cells in basement membrane matrix is drawn into a ½ cc insulin syringe fitted with a 25 G needle. The needle is inserted tangentially into the 4th inguinal mammary fat pad, and the cell-matrix mixture is deposited slowly within the glandular stroma. The needle is held in place for 10–15 seconds post-injection to minimize reflux. The skin is closed with surgical adhesive or a single wound clip, and mice are recovered on a heated pad under continuous observation until fully ambulatory.
6. Baseline Bioluminescence Imaging & Tumor Surveillance: Beginning at day 7–10 post-implantation, mice are imaged weekly via an in vivo imaging system (IVIS or equivalent). Each mouse receives an intraperitoneal injection of D-luciferin (150 mg/kg body weight), is anesthetized with isoflurane, and positioned for dorsal and ventral image acquisition. Regions of interest are drawn over the mammary gland to quantify primary tumor photon flux, establishing baseline signal intensity and tracking exponential growth. In parallel, tumor dimensions are measured twice weekly with digital calipers, and volume is calculated using the modified ellipsoid formula (length × width² × 0.5).
7. Therapeutic Intervention & Longitudinal Response Monitoring: Once tumors reach a protocol-defined size or BLI signal threshold—commonly 100–200 mm³ or a predetermined photon flux—mice are randomized into vehicle control and treatment cohorts. Investigational agents (e.g., selective estrogen receptor modulators, aromatase inhibitors, CDK4/6 inhibitors, or combination regimens) are administered according to the study design. BLI and caliper measurements are collected concurrently throughout the treatment phase to capture both metabolic viability (bioluminescence) and physical dimensions (caliper), providing dual-readout pharmacodynamic assessment.
8. Terminal Endpoint & Multi-Parameter Analysis: At study termination—when vehicle tumors approach institutional size limits (typically ~1,500 mm³ or 10–12 weeks post-implantation)—mice are euthanized and subjected to ex vivo BLI of harvested mammary tumors to confirm signal localization and intensity. Primary tumors are excised en bloc, weighed, and photographed. Tissue is snap-frozen for Western blot or RNA analysis, fixed in 10% neutral buffered formalin for paraffin embedding and H&E staining, and subjected to immunohistochemistry for Ki67, ERα, PR, phospho-Rb, cleaved caspase-3, and CDK4/6 pathway markers. Plasma may be collected for pharmacokinetic, estradiol level, and drug concentration analysis.

Fig 2. MCF-7-luc Orthotopic Mouse Model construction workflow.

Case Study-MCF-7-luc Orthotopic Mouse Model Development

In a recent preclinical engagement, Alfa Cytology established an orthotopic MCF-7-luc xenograft to evaluate the temporal pharmacodynamics of a CDK4/6 inhibitor administered as monotherapy and in combination with an aromatase inhibitor. Following estrogen pellet priming and mammary fat pad implantation in athymic nude mice, tumor-bearing animals were randomized into vehicle, CDK4/6 inhibitor monotherapy, aromatase inhibitor monotherapy, and combination therapy cohorts once bioluminescence signal reached a protocol-defined threshold. Treatment was administered over an 8-week window, with weekly IVIS imaging and twice-weekly caliper measurements performed concurrently. The combination arm demonstrated a marked deceleration in photon flux accumulation as early as week 2—preceding measurable divergence in caliper-derived tumor volume by approximately 10 days—while the CDK4/6 inhibitor monotherapy showed cytostatic BLI plateau without significant volume regression. Terminal immunohistochemistry confirmed reduced Ki67 and phospho-Rb staining in all treated cohorts, with the combination group exhibiting the most pronounced G1 arrest signature. These temporally resolved BLI data provided early pharmacodynamic evidence that complemented traditional endpoint analysis, informing dose-schedule optimization for subsequent IND-enabling pharmacology studies.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your MCF-7-luc orthotopic program grants access to a CRO that has built its imaging infrastructure and quality systems around the unique demands of BLI-enabled, estrogen-dependent xenografts. We understand that luciferase signal fidelity and hormonal priming precision are non-negotiable prerequisites for interpretable longitudinal data.

• MCF-7-luc master cell banks are maintained under continuous antibiotic selection with periodic STR authentication against ATCC HTB-22-LUC2, mycoplasma screening, and pre-batch luminometer validation to ensure reporter expression stability.
• Our in-house IVIS or equivalent bioluminescence imaging platform is calibrated for quantitative photon-flux measurement with standardized region-of-interest analysis, background subtraction, and automated reporting pipelines.
• Surgical and endocrinology teams coordinate estrogen pellet implantation with orthotopic cell inoculation to synchronize hormonal priming, achieving high tumor take rates and consistent BLI baseline establishment within 7–10 days.
• Dual-readout study designs capture both bioluminescence signal dynamics and caliper-derived tumor dimensions, enabling early detection of cytostatic drug effects that precede physical volume changes by days to weeks.
• Flexible protocols accommodate single-agent endocrine therapy, CDK4/6 combination arms, sequential treatment schedules, and long-term acquired resistance modeling under continuous therapeutic pressure with intermittent BLI monitoring.
• Terminal analysis packages integrate ex vivo BLI confirmation, ERα/PR IHC, Ki67 proliferation indices, phospho-Rb and CDK pathway markers, apoptosis readouts, and RNA-seq—providing mechanistic depth alongside temporal efficacy data.
• All procedures are conducted under IACUC oversight with AAALAC-aligned welfare standards, generating audit-ready documentation and imaging archives suitable for IND submissions, investor presentations, and peer-reviewed publication.

Contact Us

If your preclinical strategy calls for an estrogen-responsive, image-guided luminal A model that delivers real-time tumor viability data through bioluminescence imaging, Alfa Cytology's MCF-7-luc orthotopic service provides the temporal resolution and scientific rigor your program requires. Reach out to us today to discuss your BLI imaging requirements, review our MCF-7-luc quality control and validation protocols, and receive a customized study proposal with dual-readout endpoint packages tailored to your endocrine therapy or CDK4/6-targeted development strategy.

For research use only. Not intended for any clinical use.